SAN DIEGO (BUSINESS WIRE) #RVNCstock Robbins Geller Rudman & Dowd LLP announces that purchasers of Revance Therapeutics, Inc. (NASDAQ: RVNC) securities between November 25, 2019 and October 11, 2021, inclusive (“Class Period”) have until this upcoming Tuesday, February 8, 2022, to seek appointment as lead plainti.